Kebriaei Partow, Kelly Susan S, Manuri Pallavi, Jena Bipulendu, Jackson Rineka, Shpall Elizabeth, Champlin Richard, Cooper Laurence J N
Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
Front Biosci (Schol Ed). 2012 Jan 1;4(2):520-31. doi: 10.2741/282.
Adoptive transfer of antigen-specific T cells is a compelling tool to treat cancer. To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens, robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve the potency of genetically modified T cells. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, antitumor activity, paving the way for multi-center trials to establish the efficacy of this novel T-cell therapy.
抗原特异性T细胞的过继性转移是一种用于治疗癌症的有效工具。为了克服限制内源性适应性免疫对肿瘤相关抗原作出反应的免疫耐受问题，人们已经构建了强大的系统，用于对表达嵌合抗原受体（CAR）以重定向特异性的T细胞进行基因改造和表征。目前正在对基因改造T细胞的持久性和归巢进行优化，以提高基因改造T细胞的效力。利用该技术的临床试验证明了其可行性，并且越来越多地显示出抗肿瘤活性，为开展多中心试验以确立这种新型T细胞疗法的疗效铺平了道路。
